Hidden mutations in immune cells linked to autoimmune disease
On Apr. 14, 2026, researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust (CUH), the…
-
-
Adaptive Inks deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases woth $890 Million
On Dec. 15, 2025, Adaptive Biotechnologies announced it has signed two non-exclusive deals with Pfizer to support research…
-
Biotechnology | Disease | Genomics | Oncology
Revolutionary blood test for ME / Chronic Fatigue unveiled
On Oct. 8, 2025, scientists at the University of East Anglia and Oxford Biodynamics announced they have developed a…
-
World-first cure for lethal skin disease achieved in landmark study
On Nov. 11, 2024, an international team of researchers has for the first time cured patients with Toxic…
-
Developmental origins of eczema and psoriasis discovered
On Jan. 21, 2021, scientists at the Wellcome Sanger Institute announced they had created a highly detailed map…
-
UNMC VA study found contaminants may increase risk of rheumatoid arthritis
On Oct. 28, 2020, researchers at the University of Nebraska Medical Center (UNMC) reported the results of a…
-
COVID-19 | Disease | FDA | Therapeutics
City of Hope doctors lead novel clinical trial to treat cancer patients with COVID-19
On Sept. 1, 2020, City of Hope announced that it was investigating an innovative treatment for cancer patients…
-
Largest global study on hydroxychloroquine safety finds increased cardiovascular risk with azithromycin
On Aug. 24, 2020, the combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including…
-
Sorrento Announced Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
-
Mylan and Fujifilm Kyowa Kirin Biologics announced FDA approval of Hulioﾮ (adalimumab-fkjp)
On Jul. 9, 2020, Mylan and Fujifilm Kyowa Kirin Biologics announced the FDA had approved Hulioﾮ (adalimumab-fkjp), a…
-
Lilly begans phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients
On Jun. 15, 2020, Eli Lilly announced that the first patient has been enrolled in a Phase 3…
-
Potential treatment for COVID-19 identified by BenevolentAI using artificial intelligence enters randomised clinical trial
On Apr. 10, 2020, BenevolentAI announced that baricitinib, which it had identified as a potential treatment for COVID-19,…
-
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
-
Clinical trial for severely ill COVID-19 patients begun at Montefiore-Einstein
On Apr. 3, 2020, Montefiore Health System and Albert Einstein College of Medicine started treating very sick COVID-19…
-
Mylan ramped up U.S. manufacturing of hydroxychloroquine sulfate tablets to meet potential COVID-19 patient needs
On Mar. 19, 2020, Mylan announced its continued commitment to do its part in support of public health…
-
FDA Approves Tocilizumab for Treatment of Rheumatoid Arthritis
On Jan. 11, 2010, the U.S. Food and Drug Administration (FDA) approved Genentech’s tocilizumab (Actemra) for the treatment…
-
Rheumatoid Arthritis gene was discovered
On Nov. 8, 2007, researchers from Brigham and Women’s and MIT’s Broad Institute and Harvard discovered a gene…
-
Biotechnology | Disease | FDA | Medicine | Therapeutics
Long-term efficacy and safety of etanercept was found in children with polyarticular-course juvenile rheumatoid arthritis
On Jan. 10, 2003, long-term efficacy and safety of etanercept (Enbrel) was found in children with polyarticular-course juvenile…
-
Immunex received FDA approval to market Enbrel for treatment of moderate to severe rheumatoid arthritis
On Nov. 10, 1998, Immunex announced that ENBREL(tm) (etanercept) had received approval from the U.S. Food and Drug…
-
Immunex dedicated its new manufacturing and development center
In 1998, Immunex dedicated its new manufacturing and development center. The 100,000 square foot complex broke ground in…
-
A controlled trial of showed low-dose methotrexate to be effective in resistant Juvenile rheumatoid arthritis
On Apr. 16, 1992, a controlled trial of showed low-dose methotrexate to be effective in resistant Juvenile rheumatoid…
-
H. Stewart Parker founded Targeted Genetics Corp. in Seattle
On Jan. 1, 1989, Targeted Genetics, an Immunex Corp. spin-off in Seattle. which specialized in gene therapy, a…
-
Immunex Corporation was founded
In 1981, Immunex Corporation was founded by Stephen Duzan, and Christopher Henney and Steven Gillis from the Hutchinson…
-
Centocor was founded
In 1979, Centocor was founded – one of the nation’s first biotechnology companies best known for developing Remicade…
-
American Rheumatism Association established a JRA Criteria Subcommittee of the Diagnostic and Therapeuticﾠ
In 1971, the American Rheumatism Association, now known as the American College of Rheumatology, established a ‘Juvenile rheumatoid…
-
The FDA approved methotrexate, an antimetabolite derived from folic acid, and 6-mercaptopurine as anticancer drugs
On Dec. 7, 1953, the U.S. Food and Drug Administration (FDA) approved Dava Pharmaceuticals’ methotrexate oral tablet, an…
-
Drs. Edward C Kendall and Philip S Hench at the Mayo Clinic, shared the Nobel Prize in medicine
In 1950, Drs. Edward C. Kendall and Philip S. Hench at the Mayo Clinic, along with Tadeus Reichstein,…
-
A patient at Saint Marys Hospital received the first injection of Compound E (Cortisone) for rheumatoid arthritis
On Sept. 21, 1948, a 28-year-old woman at Saint Marys Hospital (Mayo Clinic) in Rochester, MN received the…
-
Canadian Red Cross Memorial Hospital,Taplow, was built for children with juvenile rheumatoid arthritis
In 1946, The Canadian Red Cross Memorial Hospital,Taplow, Berkshire, was built as a hospital for children which would…
